Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04680975
Previous Study | Return to List | Next Study

Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis (dcSSC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04680975
Recruitment Status : Recruiting
First Posted : December 23, 2020
Last Update Posted : September 16, 2021
Sponsor:
Information provided by (Responsible Party):
Kadmon Corporation, LLC

Brief Summary:
This is a phase 2, open-label, single-cohort, multicenter trial of belumosudil in subjects with Diffuse Cutaneous Systemic Sclerosis (dcSSc). An estimated total of 12 to 15 subjects will receive belumosudil 200 mg administered orally (PO) twice daily (BID) for 52 weeks. The primary analysis will be at 24 weeks.

Condition or disease Intervention/treatment Phase
Diffuse Cutaneous Systemic Sclerosis Drug: Belumosudil Phase 2

Detailed Description:

The primary objective of this phase 2, open-label, single-cohort, multicenter trial is to evaluate the efficacy of belumosudil 200 mg BID using the Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) after 24 weeks of therapy. The duration of the study will be approximately 14 months (4 weeks for screening, 52 weeks of dosing period, and 4 weeks of Follow-up)

Subjects who have signed an Institutional Review Board/Independent Ethics Committee-(IRB/IEC)-approved informed consent form (ICF) and met all of the inclusion/exclusion criteria will be enrolled. A total of 12 to 15 to subjects at approximately 5 to 6 sites will receive belumosudil 200 mg in tablet form administered PO BID for 52 weeks. The total duration of the study is approximately 14 months: a 4-week screening period, a 52-week treatment period, and a 4-week follow-up.

The primary endpoint will be analyzed using Week 24 data.

Efficacy will be assessed throughout the 52-week dosing period using:

  • Composite Response Index in Systemic Sclerosis (CRISS)
  • Modified Rodnan Skin Score (mRSS)
  • Pulmonary Function Tests (PFTs)
  • Physician Global Assessment
  • Patient Global Assessment

Safety will be assessed throughout the study and will include:.

  • Physical examinations (PEs)
  • Vital sign measurements
  • Weight measurements
  • Blood sample collection for hematology and chemistry; urinalysis
  • Electrocardiograms (ECGs)
  • Adverse event (AE) assessments
  • Concomitant medication assessments
  • Pregnancy testing for females of childbearing potential.

Reasons for discontinuation of treatment because of toxicity will be documented. Careful monitoring of all toxicities will be carried out. Dosing can be reduced 1 dose level. If the dose is not tolerated, then the subject will be discontinued from the study. If there is a interruption of dosing, after 14 days the subject will be discontinued from the study.

Subjects will be given a study drug diary to record the details of each dose of belumosudil 200 mg. Diaries will be dispense/collected on each visit. Compliance with dosing will be confirmed using subject diaries, which will be examined at each visit by site staff to determine if dosing is as instructed per protocol and follow-up.

A 4-Week Safety Follow-up Visit will occur 28 days (± 3 days) after the last dose of study drug.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Belumosudil 200 mg PO BID
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Open-label Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Actual Study Start Date : December 24, 2020
Estimated Primary Completion Date : October 1, 2022
Estimated Study Completion Date : October 1, 2022


Arm Intervention/treatment
Experimental: Belumosudil 200 mg PO BID
Subjects will receive open-label belumosudil 200 mg orally twice daily
Drug: Belumosudil
12 to 15 subjects with dcSSc will receive belumosudil 200 mg PO BID for 52 weeks
Other Name: KD025




Primary Outcome Measures :
  1. Efficacy: CRISS at Week 24 [ Time Frame: 24 weeks ]

    The primary efficacy endpoint is the effect of belumosudil 200 mg BID on the Combined Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS) after 24 weeks of therapy with belumosudil 200 mg PO BID at the end of Week 24 in the Modified Intent-to-Treat (mITT) Population.

    The CRISS exponential algorithm determines the predicted probability of improvement from baseline, incorporating changes in mRSS, FVC% predicted, SHAQ-DI, and physician and Patient Global Assessments. The outcome is a continuous variable between 0.0 and 1.0 (0-100%). A higher score indicates greater probability of improvement. A CRISS score ≥ 20% is considered a clinically meaningful improvement.



Secondary Outcome Measures :
  1. Efficacy: CRISS at Weeks 8, 16, 36, and 52 [ Time Frame: Up to 52 weeks ]
    The efficacy of belumosudil 200 mg PO BID after 8 weeks, after 16 weeks, after 36 weeks, and after 52 weeks.

  2. Efficacy: mRSS at Week 24 [ Time Frame: 24 weeks ]
    The efficacy of belumosudil 200 mg PO BID as measured by the Modified Rodnan Skin Score after 24 weeks The mRSS is a measure of skin thickness rated with scores ranging from 0 (normal) to 3 (severe skin thickening) across 17 different sites. The total score is the sum of the individual skin scores in the 17 body areas (i.e., face, hands, fingers; proximal area of the arms, distal area of the arms, thorax, abdomen; proximal area of the legs, and distal area of the legs, feet), yielding a range of 0 to 51 units.

  3. Efficacy: Forced Vital Capacity (FVC) at Week 24 [ Time Frame: 24 weeks ]
    The efficacy of belumosudil 200 mg PO BID as measured by the Forced Vital Capacity after 24 weeks of therapy.

  4. Efficacy: Physician Global Assessment at Week 24 [ Time Frame: 24 weeks ]

    The efficacy of belumosudil 200 mg PO BID at Week 24 as measured by the Physician Global Assessment after 24 weeks of therapy.

    The Physician Global Assessment is based on a single question: "How was your overall health during the last week?" The investigator uses a Visual Analog Scale (VAS) to answer in a range from 0 (extremely poor) to 100 (excellent).


  5. Efficacy: Patient Global Assessment at Week 24 [ Time Frame: 24 weeks ]

    The efficacy of belumosudil 200 mg PO BID at Week 24 as measured by the Patient Global Assessment after 24 weeks of therapy.

    The Patient Global Assessment is based on a single question: "How was your overall health during the last week?" The patient uses a Visual Analog Scale (VAS) to answer in a range from 0 (extremely poor) to 100 (excellent).


  6. Efficacy: Change in FVC at Weeks 8, 16, 36, and 52 from Baseline [ Time Frame: Up to 52 weeks ]
    The differences in FVC from baseline after 8 weeks, after 16 weeks, after 36 weeks, and after 52 weeks of therapy.

  7. Efficacy: Change in mRSS at Weeks 8, 16, 36, and 52 from Baseline [ Time Frame: Up to 52 weeks ]
    The differences in mRSS score from baseline after 8 weeks, after 16 weeks, after 36 weeks, and after 52 weeks of treatment with belumosudil 200 mg BID.

  8. Efficacy: Change in Physician Global Assessment at Weeks 8, 16, 36, and 52 from Baseline [ Time Frame: Up to 52 weeks ]
    The differences in Physician Global Assessment score from baseline after 8 weeks, after 16 weeks, after 36 weeks, and after 52 weeks of treatment with belumosudil 200 mg BID.

  9. Efficacy: Change in Patient Global Assessment at Weeks 8, 16, 36, and 52 from Baseline [ Time Frame: Up to 52 weeks ]
    The differences in Patient Global Assessment score from baseline after 8 weeks, after 16 weeks, after 36 weeks, and after 52 weeks of treatment with belumosudil 200 mg BID.

  10. Efficacy: Change in SHAQ--DI at Weeks 8, 16, 36, and 52 from Baseline [ Time Frame: Up to 52 weeks ]
    The differences in SHAQ--DI score from baseline after 8 weeks, after 16 weeks, after 36 weeks, and after 52 weeks of treatment with belumosudil 200 mg BID.

  11. Safety: Percentage of Subjects with TEAEs [ Time Frame: Up to 56 weeks: 52 weeks of treatment and 4-week follow-up ]
    The proportion of subjects who experience a treatment-emergent adverse event (TEAE), including severity and relationship to belumosudil 200 mg PO BID at all visits.

  12. Safety: Percentage of Subjects with SAEs [ Time Frame: Up to 56 weeks: 52 weeks of treatment and 4-week follow-up ]
    The proportion of subjects who experience a serious adverse event (SAE), including severity and relationship to belumosudil 200 mg PO BID at all visits.


Other Outcome Measures:
  1. Exploratory Pharmacodynamics: Association of DNN-derived Fibrosis Score with Skin Gene Expression [ Time Frame: 52 weeks ]
    Measure the correlation between DNN-derived Fibrosis Score and Skin Gene Expression in dcSSc subjects receiving belumosudil 200 mg PO BID after 52 weeks of treatment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male and female subjects ≥ 18 years old with the diagnosis of dcSSc according to the 2013 American College of Rheumatology and European League Against Rheumatism
  2. Must have disease duration (defined as interval from first non Raynaud disease manifestation) of ≤ 6 years
  3. Must have mRSS of ≥ 15 but ≤ 40
  4. Must have active disease as determined by the Principal Investigator within the 6 months prior to screening
  5. Adequate organ and bone marrow functions evaluated during the 28 days prior to enrollment as follows:

    1. Absolute neutrophil count ≥ 1.5 × 10^9/L
    2. Platelet count ≥ 100 × 10^9/L
    3. Total bilirubin ≤ 1.0 × upper limit of normal (ULN)
    4. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and serum creatinine ≤ 1.5 × ULN.
  6. Female subjects of childbearing potential have a negative pregnancy test at screening. Females of childbearing potential are defined as sexually mature women without prior hysterectomy or who have had any evidence of menses in the past 12 months. However, women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, anti-estrogens, or ovarian suppression.

    1. Women of childbearing potential (i.e., menstruating women) must have a negative urine pregnancy test (positive urine tests are to be confirmed by serum test) documented within the 24-hour period prior to the first dose of study drug.
    2. Sexually active women of childbearing potential enrolled in the study must agree to use two forms of accepted methods of contraception during the course of the study and for 3 months after their last dose of study drug. Effective birth control includes (i) intrauterine device plus 1 barrier method; (ii) on stable doses of hormonal contraception for at least 3 months (e.g., oral, injectable, implant, transdermal) plus 1 barrier method; or (iii) 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm), or a vasectomized partner.
  7. For male patients who are sexually active and who are partners of premenopausal women: agreement to use 2 forms of contraception as in criterion number 6b above during the treatment period and for at least 3 months after the last dose of study drug.
  8. Male subjects must not donate sperm for 3 months after last dose of study drug.
  9. Able to provide written informed consent prior to the performance of any study-specific procedures.

Exclusion Criteria:

  1. Subject has corrected QT interval using Fridericia's formula (QTcF) > 450 ms
  2. Ongoing use or current use of concomitant medication known to have the potential for QTc prolongation
  3. Female subject who is pregnant or breastfeeding.
  4. Participated in another study with an investigational drug within 28 days of study entry (for studies involving biologics, within 3 half-lives of the biologic).
  5. History or other evidence of severe illness or any other conditions that would make the subject, in the opinion of the Investigator, unsuitable for the study.
  6. Chronic heart failure with New York Heart Association Classes II, III, or IV.
  7. Acute or chronic liver disease (e.g., cirrhosis)
  8. Positive human immunodeficiency virus (HIV) test.
  9. Active hepatitis C virus (HCV), hepatitis B virus (HBV), or positive whole blood tuberculin test.
  10. Diagnosed with any malignancy within 3 years of enrollment, with the exception of basal cell or completely resected squamous cell carcinoma of the skin, resected in situ cervical malignancy, resected breast ductal carcinoma in situ, or low risk prostate cancer after curative resection.
  11. Has had previous exposure to belumosudil or known allergy/sensitivity to belumosudil, or any other Rho-associated Protein Kinase-2 (ROCK2) inhibitor.
  12. Scleroderma renal crisis within 4 months prior to enrollment.
  13. FVC ≤ 50% Predicted.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04680975


Locations
Layout table for location information
United States, California
University of California, Los Angeles Medical Center Recruiting
Los Angeles, California, United States, 90095
Contact: Talaya Martinez    310-794-6213    tmmartinez@uclahs.mail.onmicrosoft.com   
Principal Investigator: Elizabeth Volkmann, MD         
United States, Connecticut
Yale University School of Medicine Recruiting
New Haven, Connecticut, United States, 06519
Contact: Alyssa Williams    203-737-5571    alyssa.williams@yale.edu   
Principal Investigator: Monique Hinchcliff, MD         
United States, Illinois
Northwestern University Recruiting
Chicago, Illinois, United States, 60611
Contact: Kathleen Aren    312-503-1824    kathleen.aren@northwestern.edu   
Principal Investigator: Chase Correia, MD         
United States, New York
Columbia University Medical Center Recruiting
New York, New York, United States, 10032
Contact: Christopher Depender    646-379-4960    cd2686@cumc.columbia.edu   
Principal Investigator: Elana Bernstein, MD         
United States, Utah
University of Utah Withdrawn
Salt Lake City, Utah, United States, 84132
United States, Washington
Virginia Mason Medical Center Terminated
Seattle, Washington, United States, 98101
Sponsors and Collaborators
Kadmon Corporation, LLC
Layout table for additonal information
Responsible Party: Kadmon Corporation, LLC
ClinicalTrials.gov Identifier: NCT04680975    
Other Study ID Numbers: KD025-215
First Posted: December 23, 2020    Key Record Dates
Last Update Posted: September 16, 2021
Last Verified: September 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Kadmon Corporation, LLC:
skin diseases
systemic sclerosis
phase 2
Scleroderma Health Assessment Questionnaire Disability Index
Modified Rodnan Skin Score
Combined Response Index in dcSSc (CRISS)
diffuse cutaneous systemic sclerosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Scleroderma, Systemic
Scleroderma, Diffuse
Sclerosis
Pathologic Processes
Connective Tissue Diseases
Skin Diseases